To date, at least 10 pegylated proteins have been approved for clinical use [15], including the anti-TNFa Fab fragment, certolizumab pegol, for the treatment of Crohn’s disease and rheumatoid arthritis. The gene discussed is TNF; the disease is rheumatoid arthritis.